Advanced in Multiple Myeloma

Martin Hoffmann

Ludwigshafen Am Rhein, RP, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Multiple Myeloma
Ludwigshafen Am Rhein, RP, DE 
OverviewLocationsClinical Research

Overview

Martin Hoffmann practices in Ludwigshafen Am Rhein, Germany. Mr. Hoffmann is rated as an Advanced expert by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Light Chain Deposition Disease (LCDD), Mantle Cell Lymphoma (MCL), Primary Amyloidosis, and Bone Marrow Transplant.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Multiple Myeloma.

Gender
Male

Locations

Ludwigshafen Am Rhein, RP 67063, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
View 1 Less Clinical Trial

14 Total Publications

Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma.
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma.
Journal: Scientific reports
Published: March 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hoffmann's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile